Granules India Q1 FY27 Earnings Call Transcript Released
Granules India reported a strong Q1 FY27 with 22% YoY revenue growth to INR 1,477 crore and 60% PAT growth to INR 180 crore. EBITDA rose 37% to INR 339 crore. The company is focusing on complex generics (50% of finished dosages) and its peptide CDMO business. Remediation at Gagillapur is nearing completion. Capex for FY27 is guided at INR 600 crore.
The announcement details strong financial performance, strategic advancements in key business segments (complex generics, peptide CDMO), and progress on regulatory fronts, all of which are material to investors and significantly influence the company's valuation and future prospects.
The company reported strong financial results with significant year-on-year growth in revenue, EBITDA, and profit after tax. Key operational and strategic milestones were achieved, including progress in remediation, growth in complex generics and peptide CDMO, and a near-zero debt to EBITDA ratio, indicating a positive outlook.
Granules India Limited has released the transcript of its Earnings Conference Call for the first quarter of FY27. The call, held on July 21, 2026, featured insights from Chairman and Managing Director Dr. Krishna Prasad Chigurupati, Executive Director Ms. Priyanka Chigurupati, CFO Mr. Mukesh Surana, and other key management personnel. The management highlighted a strong performance in Q1 FY27, with revenue growing 22% year-on-year to approximately INR 1,477 crore. EBITDA increased by 37% to INR 339 crore, and profit after tax grew by 60% to INR 180 crore. The company noted a significant improvement in return on capital to 18% and a near-zero net debt to EBITDA ratio. The company is strategically moving up the value chain, focusing on complex generics, which now constitute 50% of finished dosages, and its peptide CDMO business, which grew over 100% last year. The remediation work at the Gagillapur facility is largely complete, with 7 out of 8 facilities having a clean EIR, and 9 applications are ready for launch pending FDA clearance. The company discussed its medium-term strategy involving differentiated 505(b)(2) products and first-to-file opportunities, and long-term exploration of larger opportunities in non-solid dosage areas. The peptide CDMO platform aims for a 5x revenue growth in 5 years, targeting USD 50 million revenue with over 30% EBITDA by the mid-third year. For FY27, the company anticipates continued growth, with capex guidance of INR 600 crore. R&D expenses are expected to be around 5.5% to 6% of sales, with a majority of the spend directed towards complex generics.
What to do with a filing like this
Granules India Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Granules India Limited. Read the original for the full detail.